Epilepsy

Study findings have shown sustained improvements in seizure-freedom rates and functional outcomes in a cohort of adults that mirror prior findings in pediatric populations.

An 8 year old boy with genetically confirmed neurofibromatosis type 1 presents with first generalized seizure.

The director of the Epilepsy Center and vice chair of the Neurological Institute for Strategy and Development at Cleveland Clinic relayed his excitement for a new advanced imaging tool that could change how epilepsy specialists diagnose and treat the disease.

Imad Najm, MD, details how advanced telemedicine technology has created a paradigm shift in the way physicians see and treat patients at Cleveland Clinic and around the world.

UCB’s intranasal midazolam spray (Nayzilam), an FDA-approved therapy for seizure clusters, has shown success and rapid efficacy in status epilepticus, with treatment effect occurring approximately 4 to 5 minutes post-administration.

The director of the Epilepsy Center at Cleveland Clinic spoke about the challenges faced when identifying focal cortical dysplasia.

Study results suggest that as many as 20% of patients may be nonadherent to medication regimens, with youth having the strongest association with intentional nonadherence.

The chief medical executive at The University of Texas MD Anderson Cancer Center is expected to be named the next commissioner of the FDA by President Donald Trump.

Analysis of long-term safety of intranasal diazepam shows favorable results in children and adolescents with cluster or acute, repetitive seizures.

Epilepsy-specific TRAQ questionnaire shows high validity in pediatric epilepsy patients transitioning to adult epilepsy care.

Data presented at the Child Neurology Society Annual Meeting suggest that the safety and efficacy of cannabidiol (Epidiolex; GW Pharmaceuticals) is maintained through 72 weeks of treatment for patients with LGS.

The associate professor of clinical pediatrics and neurology at Ohio State University and section chief of pediatric neurology at Nationwide Children’s Hospital stresses the importance of broadcasting correct information to the public concerning epilepsy.

A pooled analysis of 2 phase 3 trials of fenfluramine demonstrate the clinical potential of the drug for patients with Dravet syndrome.

Ganaxolone proves effective in phase 2 trial in patients with status epilepticus, with a median time to status cessation of 5 minutes.

The section chief of pediatric neurology at Nationwide Children’s Hospital discusses the realities parents face when exploring CBD to treat epilepsy.

New study results suggest that a wearable ECG device can predict nonconvulsive seizures with a sensitivity of 93.1% and all seizures with a sensitivity of 90.5%.

The director of pediatric epilepsy at Northeast Regional Epilepsy Group and co-director of epileptology at Hackensack University Medical Center provided context to these findings to explain how soticlestat can address challenges in developmental epileptic encephalopathies, as well as what may be next in its advancement.

The director of pediatric epilepsy at Northeast Regional Epilepsy Group and co-director of epileptology at Hackensack University Medical Center spoke about soticlestat and what can be gleaned from data thus far.

Recent study results suggest that relative seizure reduction is an equivalent predictor of post-surgery quality of life in epilepsy to seizure freedom. Study author Lara Jehi, MD, offered insight into the value of these data.

Relative seizure reduction was as equally strong a predictor of patient quality of life after epilepsy surgery as seizure freedom in a recent study, with absolute reduction proving to be the worst model surveyed.

In an interview with NeurologyLive, Dennis Lal, PhD, discusses the value of genetic testing and how it can optimize the way we develop clinical trials and test new therapies.

A newborn presents with new onset episodes of lateral gaze deviation with extremity stiffening.

Neurology News Network for the week ending October 5, 2019.

A newborn presents with new onset episodes of lateral gaze deviation with extremity stiffening.

Following the receipt of a refusal to file letter from the FDA, Zogenix has resubmitted its application for fenfluramine hydrochloride (Fintepla), seeking approval for the treatment of seizures associated with Dravet syndrome.

The professor of medicine, neurology, at the University of Toronto shared insight into the importance of communication and a good network of physicians to an adult neurologist caring for patients with epilepsy.

The professor of medicine, neurology, at the University of Toronto discussed the best ways for adult neurologists to ensure a smooth transition of care for patients with epilepsy entering their care.

The professor of medicine, neurology, at the University of Toronto discussed the best ways for pediatric neurologists to ensure a smooth transition of care for patients with epilepsy who are leaving the pediatric system.

The 1st Annual Congress on the Future of Neurology will take place September 27-28, 2019 at the InterContinental New York Times Square in New York City.

The director of the adult epilepsy center at Washington University in St. Louis discussed the takeaways for clinicians regarding the use of intranasal diazepam as a treatment for runs of seizures in patients with refractory epilepsy.